Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapyESMO Open 2022 Apr 08;7(2)100463, E Grande, T Alonso-Gordoa, O Reig, E Esteban, D Castellano, X Garcia-Del-Muro, MJ Mendez, J García-Donas, M González Rodríguez, JA Arranz-Arija, P Lopez-Criado, J Molina-Cerrillo, B Mellado, C Alvarez-Fernandez, G De Velasco, MA Cuéllar-Rivas, RM Rodríguez-Alonso, JF Rodríguez-Moreno, C Suarez-Rodriguez
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.